The Cancer Letter

Inside information on cancer research and drug development

Clinical Roundup

Lower MRD prior to HCT associated with better outcomes in FLT3-ITD AML

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

Patients in remission after being treated for a high-risk blood cancer are likely to have better outcomes if no trace of the cancer is detectable before the patients receive donor blood cells.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

In Brief

Marina Konopleva joins Break Through Cancer

Marina Konopleva, director of the Leukemia Program and co-director of the Blood Cancer Institute at the Montefiore Einstein Comprehensive Cancer Center, has joined Break Through Cancer, a collaborative medical research foundation that supports teams of scientists as they advance treatments for some of the world’s deadliest cancers. 
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account